Navigation Links
Pharmacyclics First to Announce Breakthrough Therapy Designation in Oncology from the U.S. Food and Drug Administration
Date:2/12/2013

" said Bob Duggan , CEO and Chairman of the Board. "This compound entered the clinic in 2009 and has demonstrated tremendous clinical progress over the past four years. I would like to thank our collaboration partner, Janssen, for their support. Together we are committed to bringing this new therapeutic to patients and health care providers."

Dr. Ellen Sigal , Chair & Founder of Friends of Cancer Research, a think tank and advocacy organization based in Washington, D.C., said, "As an oncology product, ibrutinib receiving the Breakthrough Therapy Designation is an example of progress and hope for patients fighting a range of cancers. This designation shows that the FDA is dedicated to using an 'all hands on deck approach' to work on products that show promise in treating serious and life-threatening diseases. The breakthrough pathway that our organization worked to create is intended to speed up the development and review of treatments that may demonstrate substantial improvement over existing therapies, and ibrutinib is a great example of using this new designation to potentially accelerate patient access to promising treatments."

The FDA Breakthrough Therapy Designation for ibrutinib in MCL patients was based on data from clinical and pre-clinical studies. Ibrutinib has the potential to improve the outcome in this serious and life-threatening disease which has a poor prognosis. The company and Janssen have designed a comprehensive development program of ibrutinib in MCL which includes the following studies:
- A Phase III randomized, multi-center registration trial of ibrutinib as a monotherapy versus temsirolimus in relapsed or refractory MCL patients who received at least one prior rituximab-containing chemotherapy regimen, RAY (MCL3001).
- A Phase III randomized, double-blind, placebo-controlled study of ibrutinib plus bendamustine and rituximab
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Pharmacyclics Announces Date of Financial Results for Three and Six Months Ended December 31, 2012 and Conference Call
2. Pharmacyclics Reports Fourth Quarter and Full Year Fiscal 2012 Financial Results and Recent Developments
3. Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
4. Pharmacyclics Announces Oral Presentations and Clinical Update of Ibrutinib (PCI-32765) at the 2012 Annual Meeting of the American Society of Clinical Oncology
5. Landauer, Inc. Reports Fiscal 2013 First Quarter Results
6. Misonix Reports Financial Results for First Half of Fiscal 2013
7. CareFusion Reports First Half Fiscal 2013 Results
8. Avanir Pharmaceuticals Reports Fiscal 2013 First Quarter Financial And Business Results
9. American Pacific Reports Fiscal 2013 First Quarter Results; Reaffirms Full Year Guidance
10. European patient registry in venous thromboembolism (VTE) - PREFER in VTE - enrols first patient
11. Neutronic Ear Introduces Worlds First Rechargeable-Powered Hearing Device
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... , Aug. 27, 2015  BioElectronics Corporation (OTC Pink: BIEL), ... that three abstracts featuring the use of ActiPatch®, its ... 9 th Congress of the European Pain Federation ... September 2015. The Company will also be exhibiting ... Gianluca Bagnato , department clinical and experimental rheumatology ...
(Date:8/27/2015)... ATLANTA , August 27, 2015 ... Consortium convened in Boston on ... Consortium in an effort to more fully exploit the ... are applied to brain diseases. "As an ... has a responsibility to assume a leadership role - ...
(Date:8/27/2015)... FRANCISCO, Calif. , Aug. 27, 2015 /PRNewswire/ ... therapeutics for the treatment of cancer, today announced ... member of the company,s Board of Directors, has ... led immuno-oncology at Eli Lilly and AstraZeneca, and ... first FDA approved checkpoint inhibitor, at Bristol-Myers Squibb ...
Breaking Medicine Technology:BioElectronics Selected to Present its Pain Research and Devices at the European Pain Federation Conference 2New Elekta Consortium to Push Frontiers of Linear Accelerator-Based Stereotactic Radiation Therapy for the Brain 2New Elekta Consortium to Push Frontiers of Linear Accelerator-Based Stereotactic Radiation Therapy for the Brain 3Immuno-Oncology Veteran Rachel Humphrey, M.D., Joins CytomX as Chief Medical Officer 2Immuno-Oncology Veteran Rachel Humphrey, M.D., Joins CytomX as Chief Medical Officer 3
... PhotoMedex, Inc. (Nasdaq: PHMD ) announced ... current clinical trial being performed by John Y.M. Koo, ... of California, San Francisco. Dr. Koo,s experimental treatment protocol ... from moderate to severe psoriasis. The study, which utilizes ...
... Awarepoint Corporation announced today that CEO Jay Deady will ... Healthcare Innovation Summit on April 14, 10:30 a.m. – ... York. Joining Deady on the panel will be Harry Greenspun, ... Safavi, M.D., vice president and global lead of the Cisco ...
Cached Medicine Technology:Clinical Trial Offers New Hope for Moderate to Severe Psoriasis Sufferers 2Clinical Trial Offers New Hope for Moderate to Severe Psoriasis Sufferers 3Awarepoint CEO Jay Deady to Serve as Panelist at IBF's Digital Healthcare Innovation Summit 2Awarepoint CEO Jay Deady to Serve as Panelist at IBF's Digital Healthcare Innovation Summit 3
(Date:8/27/2015)... ... August 27, 2015 , ... Keck Graduate Institute (KGI), School of Pharmacy ... Coats at a formal ceremony recognizing them as members of the 2nd class of ... August 22. Symbolizing dedication to clinical service and patient care, the White Coat Ceremony ...
(Date:8/27/2015)... ... August 27, 2015 , ... Workflow in labs has greatly ... in the last decade. New features such as multiplexing, microfluidics, and integration ... where do lab managers, technicians, and researchers find handy metrics to compare and ...
(Date:8/27/2015)... ... 27, 2015 , ... Allegheny General Hospital (AGH), part of ... centers in the United States to receive international recognition for an advanced, innovative ... Life Support Organization (ELSO) , an international consortium of healthcare institutions dedicated to ...
(Date:8/27/2015)... ... August 27, 2015 , ... The Naderi Center is proud ... Kybella, a cutting-edge, noninvasive procedure to improve submental fat. The first and only ... results without surgery. Dr. Kulak is the only Board Certified surgeon in the ...
(Date:8/27/2015)... ... August 27, 2015 , ... More destinations and stores are ... That’s why Amica Insurance is sharing some tips to help your whole family travel ... million people travel with pets each year. Amica is sharing the following tips from ...
Breaking Medicine News(10 mins):Health News:KGI School of Pharmacy’s 2nd Annual White Coat Ceremony a Success 2Health News:KGI School of Pharmacy’s 2nd Annual White Coat Ceremony a Success 3Health News:KGI School of Pharmacy’s 2nd Annual White Coat Ceremony a Success 4Health News:Douglas Scientific® Webinar Outlines Comparisons of Varied qPCR Instruments 2Health News:Douglas Scientific® Webinar Outlines Comparisons of Varied qPCR Instruments 3Health News:International Organization Honors Allegheny General Hospital's Advanced Lifesaving Program for Cardiac and Respiratory Failure 2Health News:International Organization Honors Allegheny General Hospital's Advanced Lifesaving Program for Cardiac and Respiratory Failure 3Health News:International Organization Honors Allegheny General Hospital's Advanced Lifesaving Program for Cardiac and Respiratory Failure 4Health News:Noninvasive Double Chin Elimination Now Available in Herndon and Chevy Chase 2Health News:Noninvasive Double Chin Elimination Now Available in Herndon and Chevy Chase 3Health News:Amica Unleashes 5 Tips for Safe Traveling with Pets 2
... 14 (HealthDay News) -- An international team of researchers has ... restless legs syndrome. Restless legs syndrome is a condition ... in the legs, relieved only by movement. One of the ... sleep loss, daytime fatigue and even depression. In ...
... THURSDAY, July 14 (HealthDay News) -- Heart disease patients ... painkillers called non-steroidal anti-inflammatory drugs (NSAIDs) are at greater ... research shows. NSAIDS include popular medications such ... naproxen (Aleve). The results are published in the July ...
... not only cost-effective for treating people who are severely obese, ... a new study from Washington University School of Medicine in ... all obese people, the researchers say. Patients who have ... time and have fewer medical problems related to their weight, ...
... , THURSDAY, July 14 (HealthDay News) -- New ... style about interactions with other people could help them ... adulthood. Researchers from Oxford University in the United ... toward either positive or negative interpretations of unclear social ...
... patients in this study in whom a reference committee ... been misdiagnosed by their family doctors as not having ... the results of their cross-sectional study in the current ... Int 2011; 108[26]: 445-51). When a patient presents ...
... young athletes collapsing during sports practice due to an ... health care professionals to call for mandatory electrocardiogram (ECG) ... validity of such a mandate. A new study ... Pediatrics examines the accuracy and effectiveness of pre-sport ...
Cached Medicine News:Health News:Certain Painkillers May Raise Odds of Stroke, Heart Attack: Study 2Health News:Weight-loss surgery cost-effective for all obese 2Health News:Weight-loss surgery cost-effective for all obese 3Health News:Training in Positive Thinking May Help Anxious Teens 2Health News:Sudden cardiac death in young athletes: Study suggests many ECG screenings are inaccurate 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: